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Ablation of Scar or Arrhythmia?*Roderick Tung, MD,y Hans Kottkamp, MDzSEE PAGE 2872C atheter ablation of ventricular tachycardia(VT) reduces recurrent VT across multipleclinical settings, from electrical storm to
pre-emptive therapy after a ﬁrst occurrence of VT
(1). Approaches for ablation include targeting the
arrhythmia using electrophysiological approaches
(entrainment mapping, pacemapping, and electroa-
natomic mapping) and substrate modiﬁcation to
reduce the arrhythmogenicity of a scar. Superiority of
a single approach has not been demonstrated consis-
tently, although recent trends associate more exten-
sive ablation with less VT recurrence (2–4). There
is inconclusive evidence that mapping during VT
improves long-term ablation success compared with
a substrate-based approach in sinus rhythm (5,6).
“Substrate-based” approaches use electroanatomic
mapping to carry out ablation predominantly during
sinus rhythm and have variable, operator-dependent
interpretations. Although many centers undertake a
reﬁned search for an induced VT morphology, others
ablate the scar without any speciﬁc arrhythmia
targeting. The rationale for the latter approach is
that more extensive tissue destruction is necessary to
emulate surgical resection. Furthermore, most pa-
tients have multiple VTs and the search for a single
isthmus may be distracting and time-consuming. The
counter argument is that not all low-voltage regions
are critical components of re-entrant circuits, and
methods that identify the most arrhythmogenic areas*Editorials published in Journal of the American College of Cardiology
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yield regions (7) and avoid unnecessary ablation at
bystander sites.The multicenter, prospective, randomized trial
presented by Di Biase et al. (8), in this issue of the
Journal, compares a “scar-based” with a “VT-based”
strategy. In this study 118 patients with post-infarct
cardiomyopathy and recurrent stable VT were ran-
domized to ablation limited to “clinically stable”
induced VTs versus an extensive homogenization
strategy. In the limited strategy arm, only induced
clinical and hemodynamically stable VTs were tar-
geted using standard entrainment and pacemapping
techniques, and ablation was conﬁned to scar regions
that were characterized as isthmuses. In the homog-
enization arm, extensive ablation was performed
throughout scar, targeting all local potentials with
fractionation and locally delayed activity and the
low-voltage regions were remapped as an endpoint to
demonstrate elimination of abnormal electrograms.
Epicardial ablation was performed only in patients
that remained inducible for clinical VT endocardial
strategies.
Less recurrent VT occurred in the homogenization
group compared with the limited approach for clinical
VTs (84.5% vs. 51.7%; p < 0.001) at 1-year follow-up.
No differences in mortality were observed, but a
decrease in rehospitalization was observed in pa-
tients treated with a homogenization approach. No
differences in post-ablation ejection fraction were
observed between the 2 approaches, lessening con-
cerns that deterioration in systolic function may
result from extensive ablation.
Several aspects of the study warrant discus-
sion. VT induction was not required in the scar
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went induction of VT at the operator’s discretion,
suggesting that many patients had a hybrid approach
including targeting of induced VTs. This may have
enhanced the efﬁcacy of the homogenization arm.
The authors suggest that procedural time was shorter
with a scar-based strategy compared with an
arrhythmia-based approach once these cases were
excluded from analysis. Additionally, 13% of patients
assigned to ablation of clinically stable VTs had
adjunctive hemodynamic support, illustrating that
unstable VTs were likely targeted in such patients.
Finally, an additional on-treatment variable of total
radiofrequency application time (35 vs. 68 min) must
be factored in to account for the difference in efﬁcacy.
This study enrolled patients with drug-refractory,
hemodynamically tolerated VT, and thus these data
are not applicable to patients with only unstable VT,
which comprise w40% of patients referred for abla-
tion (9). All patients had implantable cardioverter-
deﬁbrillators, and it is difﬁcult to ascertain the
hemodynamic stability of VT if therapies intervene
rapidly. In contrast, the VTACH study enrolled patients
with tolerated VT before implantable cardioverter-
deﬁbrillator implantation (10). Second, the determi-
nation of whether a clinical VT is “clinical” has signif-
icant limitations, because similarity in cycle length is
not as predictive as 12-lead morphology. Sedation
and anesthesia may inﬂuence the morphology and
cycle length of induced VTs (11). The imperfect and
relatively arbitrary identiﬁcation of the clinical VT
based solely on tachycardia rate is highlighted by a
mean cycle length of 399 ms among the “clinical”
VTs induced, compared with 376 ms among
“nonclinical” VTs, with a wide standard deviation
of 100 ms.
Although a scar-based strategy shifts the intra-
procedural proportion of mapping to ablation time
toward more therapeutic ablation time upstream, this
approach may have limitations because it is estimated
that up to 22% of patients with structural heart dis-
ease have focal mechanisms of arrhythmia that may
not be addressed without identiﬁcation of a targetVT (12,13). Additionally, there may be intellectual
resistance to treating VT with a purely anatomic
approach. Focused approaches may obviate ex-
tensive ablation of nonarrhythmogenic regions of
scar, which may be time-consuming and unnecessary.
A more reﬁned strategy targeting the entrances to
downstream late activation within channels holds
promise to achieve homogenization using fewer
ablation lesions with 86% to 91% freedom from VT
recurrence (14,15). Finally, there is no objective and
reproducible measure to quantify and demonstrate
elimination or modiﬁcation of an abnormal electro-
gram within scar.
The current study convincingly demonstrates that
more extensive ablation is more effective. Recurrence
rates after ablation are as high as 50% to 70% in scar-
related VT, which remains far inferior compared with
early surgical success rates in the post-infarction
setting (2,16–18). When ablating spatially complex
scar with a small-tipped catheter, redundant, multi-
ple, and expansive lesion sets are necessary to more
closely mimic surgical resection. Reﬁnements in
current ablation technology and alternative energy
sources allowing for greater destruction of arrhyth-
mogenic tissue are needed.
The authors are to be congratulated on a well-
designed, prospective, multicenter effort providing
high-level evidence advocating extensive scar modi-
ﬁcation beyond targeted and induced VTs. As more
examples of mortality reduction associated with
successful VT ablation emerge (9,19), broader and
earlier implementation is likely, which brings identi-
ﬁcation of the most optimal strategies to the forefront
of clinical investigation. Randomized, multicenter
studies in VT ablation are few to date and the present
study sets the tone for the prospective collaborative
work that lies ahead in this evolving ﬁeld.
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